Introduction {#sec1}
============

The molecular basis for the self-renewal and differentiation of human embryonic stem (ES) cells is not fully understood. In the mouse, self-renewal depends on the maintenance of a core regulatory network of three transcription factors, Nanog, Oct4, and Sox2, which function as a unit to block differentiation (reviewed in [@bib19]). Mouse embryos null for any of these factors are incapable of maintaining a pluripotent inner cell mass, and cells destined to become epiblast instead develop into extraembryonic lineages ([@bib2; @bib28; @bib8; @bib27]). The involvement of these transcription factors has been more recently extended to human ES cells, as they occupy the promoters of a number of genes shown to be differentially upregulated or repressed in human ES cells versus differentiated cells ([@bib3]). Unlike mouse ES cells, these three factors do not function as a unit to regulate self-renewal of human ES cells and each represses the differentiation of different cell fates ([@bib37]).

Little is known about the factors working with either NANOG, OCT4, or SOX2 to block lineage specific differentiation in human ES cells. Co-immunoprecipitation experiments have been successfully utilized to detect proteins binding to and cooperating with Nanog, Oct4, and Sox2 in mouse ES cells ([@bib36; @bib23; @bib35; @bib24; @bib30]). We would like to develop a complementary forward genetic approach to identify genes that cooperate with a factor such as NANOG in regulating important biological processes in human ES cells. A forward genetic approach not only has the power to interrogate the genome in an unbiased fashion, but also has the potential to identify cooperating genes that are either not in the same protein complex or have low transcript or protein abundance.

We have previously shown that the *piggyBac* (*PB*) transposon modified from moth can efficiently transpose in the mouse and human genomes ([@bib14]). Here we present a gain of function screen in human ES cells using *PB* transposon mutagenesis. The transposon is specially designed for identifying genes that cooperate with NANOG to block differentiation and support human ES cell self-renewal. As proof of principle, we show that the screen identified *DENND2C*, whose overexpression is capable of genetic cooperation with *NANOG* to block retinoic acid (RA)-induced differentiation. Further characterization revealed that DENND2C negatively regulates RHOA, affecting the localization, activity, and DNA association of nuclear RHOA.

Results {#sec2}
=======

*PB* Insertional Mutagenesis Screen in Human ES Cells {#sec2.1}
-----------------------------------------------------

The *PB* transposon has been demonstrated to be a useful tool for efficient transgenesis and insertional mutagenesis in both mouse and human immortalized cells ([@bib14]). The transposon can efficiently mediate both loss- and gain-of-function insertional mutagenesis in mice ([@bib14; @bib32; @bib21]). Given that *PB* can also mediate efficient gene transfer in human ES cells ([@bib9]), we decided to develop a *PB* vector for insertional mutagenesis screens in human ES cells.

To identify factors that cooperate with NANOG to block RA-induced differentiation, we have taken the advantage of *PB*'s large cargo capacity to develop an insertional mutagenesis vector that can simultaneously express the *NANOG* transgene (PB\[IM,N\]; [Figure 1](#fig1){ref-type="fig"}A; [@bib14; @bib22]). PB\[IM,N\] insertion upstream of a gene results in constitutive overexpression of the downstream gene, while insertion within a transcription unit can result in overexpression of a truncated gene product downstream of the insertion site, leading to constitutive activation, dominant-negative effects, or heterozygous knockout of the gene ([Figure 1](#fig1){ref-type="fig"}A). In addition to mutagenesis, such insertions result in fluorescent labeling of mutated cells with Katushka marker. Upon co-transfection with a helper plasmid carrying the *PB* transposase transgene, PB\[IM,N\] stably integrates into the genome of about 30% of transfected human ES cells with an average of five copies of transposon per genome ([Figure 1](#fig1){ref-type="fig"}B; [Experimental Procedures](#sec4){ref-type="sec"}). Of 133 *PB* insertions mapped in human ES cells to date, 93% of insertions are within 200 kb of a gene, and 53% are located within an intron. This is consistent with data showing that *PB* frequently integrates near to or within coding units, making this transposon a useful tool for insertional mutagenesis of genes ([@bib14]). The puromycin antibiotic resistance marker within the construct allows for the selection of cells with stable *PB* integration. Thus, this vector allows one to generate a library of individually mutagenized human ES cells with the condition of NANOG overexpression in a quick, easy, and cost-effective fashion.

For this screen, we have used an H1 human ES cell line containing an EGFP reporter and neomycin resistance cassette knocked into the *OCT4* 3′UTR ([@bib42]; H1 *OCT4*-EGFP or WT cells). Undifferentiated cells that continue to express the self-renewal factor OCT4 are both EGFP positive and G418 resistant. We utilized PB\[IM,N\] to screen for genes capable of genetically cooperating with NANOG to block differentiation of H1 *OCT4*-EGFP human ES cells. For the screen, approximately 9.6 × 10^7^ cells were transfected in single-cell suspension with PB\[IM,N\] and the *PB* transposase transgene plasmid in 24 Matrigel-coated 6-well plates, allowing for the isolation of individual mutant clones after puromycin selection. Surviving adherent and puromycin selected cells were subsequently treated with a combination of RA and G418 in the same monolayer culture. Six surviving independent clones with undifferentiated morphology were isolated and confirmed in retesting ([Figure 1](#fig1){ref-type="fig"}C; see [Experimental Procedures](#sec4){ref-type="sec"} for details). All of these Katushka-positive clones express *OCT4*-EGFP, indicating that they remain undifferentiated ([Figure 1](#fig1){ref-type="fig"}D).

In human ES cells, the expression of a *NANOG* transgene confers inhibition of spontaneous differentiation and fibroblast growth factor (FGF) independence ([@bib41; @bib12]). In mouse ES cells, expression of a *Nanog* transgene has been shown to confer several effects, including resistance to RA-induced differentiation, leukemia inhibitory factor (LIF) independence, and increased colony formation ([@bib8; @bib27]; reviewed in [@bib29]). We confirmed that expression of NANOG by a *PB* vector in the H1 *OCT4*-EGFP cells stabilizes human ES cells to resist spontaneous differentiation (PB\[NANOG\] or NANOG; [Figure 2](#fig2){ref-type="fig"}A). Unlike in mouse ES cells, NANOG overexpression in human ES cells confers only weak resistance to RA-induced differentiation. All WT human ES cells appear morphologically differentiated in response to RA treatment ([Figure 2](#fig2){ref-type="fig"}B). This differentiation is reflected by induction of the GATA6 endoderm marker ([Figures 2](#fig2){ref-type="fig"}B and 2C). In contrast, NANOG expressing colonies after RA treatment contain small patches of cells that appear morphologically undifferentiated and continue to express NANOG ([Figures 2](#fig2){ref-type="fig"}B and 2C). This weak resistance to RA is also observed in cells transfected with the PB\[IM,N\] mutagenic construct ([Figure 2](#fig2){ref-type="fig"}D). Concordant with these results, only a few PB\[NANOG\] or PB\[IM,N\] colonies are able to survive when RA treatment is combined with G418, as differentiated cells no longer express the G418 resistance marker ([Figure 2](#fig2){ref-type="fig"}E). Thus, NANOG overexpression in human ES cells offers an ideal condition for forward genetics, as the small degree of resistance to differentiation allows for a sensitized screen without the drawback of excessive background. The clones identified from the screen display robust resistance to RA treatment in comparison to NANOG overexpressing escapers ([Figure 2](#fig2){ref-type="fig"}E). Indeed, only the identified clones can survive more than one round of RA treatment.

The *PB* insertion sites in the resistant clones were determined by PCR and sequencing ([Experimental Procedures](#sec4){ref-type="sec"}; [Table S1](#app2){ref-type="sec"}). Detailed characterization of one of the isolated clones is presented below, while other information will be described elsewhere.

Identification of *DENND2C* as a NANOG Collaborator for Blocking Differentiation {#sec2.2}
--------------------------------------------------------------------------------

The clones isolated from the screen exhibit varying degrees of blocking RA-induced differentiation and different morphologies, suggesting different underlying mechanisms of resistance ([Figure 2](#fig2){ref-type="fig"}E). Clone 2 was of particular interest to us because of its unique morphology. Cells from this clone resisted spontaneous differentiation and instead piled into dense, multilayered colonies, with some cells aggregating into balls. These cells exhibited a weak attachment to Matrigel as they are readily detached after collagenase IV treatment. Clone 2 had three *PB* insertions, the examination of which led to the identification of the causative gene, *DENND2C*. DENND2C belongs to a family of proteins containing DENN domains (Differentially Expressed in Normal versus Neoplastic; reviewed in [@bib25]). A *PB* insertion is located within an intron of the *DENND2C* gene, resulting in the overexpression of the C-terminal DENN domain of the gene while not having significant effects on the expression of surrounding genes ([Figure 3](#fig3){ref-type="fig"}A). More importantly, overexpression of the *DENND2C* gene product alone, either truncated or full length, in the NANOG-expressing parental cells phenocopies clone 2 morphology and behavior ([Figure 3](#fig3){ref-type="fig"}B). This indicates that *PB* disruption of *DENND2C* is the causative alteration ([Figures 3](#fig3){ref-type="fig"}A and 3B).

These cells maintain the expression of stemness markers OCT4, NANOG, and alkaline phosphatase and are able to form well-differentiated teratomas in mice, indicating that they are undifferentiated ([Figures 3](#fig3){ref-type="fig"}C, 3D, and [S1](#app2){ref-type="sec"}A). DENND2C expressing cells are resistant to spontaneous differentiation as well as several passages in RA-treated media; however, resistance is not observed with other differentiating agents such as 12-O-Tetradecanoylphorbol-13-acetate (TPA). Furthermore, the effects of DENND2C on colony morphology were reversible in a doxycycline-inducible system (data not shown).

By comparing cells overexpressing either DENND2C alone or DENND2C expressed in the PB\[NANOG\] background, we discovered that DENND2C alone is responsible for the morphological properties of clone 2, while cooperation of DENND2C and NANOG is responsible for blocking RA-induced differentiation ([Figures 3](#fig3){ref-type="fig"}B and 3E). This genetic cooperation is also observed in induced pluripotent stem cells co-expressing DENND2C and NANOG ([Figure S1](#app2){ref-type="sec"}B).

DENND2C Functions as a Negative Regulator of RHOA and RAC1 {#sec2.3}
----------------------------------------------------------

DENN domain proteins have been shown to function as RAB GEFs (GDP-GTP exchange factors) as well as interact with non-RAB proteins ([@bib1; @bib40]; reviewed in [@bib25]). The DENND2 subfamily consists of four members, A through D. While all four DENND2 subfamily members could behave as RAB9 GEFs by in vitro GDP release activity, the in vivo functions for DENND2B, DENND2C, and DENND2D are unknown, as only DENND2A knockdown phenocopies the lysosomal defect caused by RAB9 inactivation in HeLa cells ([@bib40]). Consistent with the previous report, we detected a lysosomal defect for DENND2A, but not for DENND2C in knockdown experiments in human ES cells ([Figure S1](#app2){ref-type="sec"}C). Furthermore, deregulation of RAB9A and B activities using dominant-negative and active mutants does not result in any of the ES cell phenotypes caused by DENND2C ([Figure S1](#app2){ref-type="sec"}D). These data indicate that DENND2C does not function as a regulator for RAB9 in human ES cells.

DENND2 proteins are expressed within the nucleus and cytoplasm of both undifferentiated and differentiated human ES cells ([Figure S1](#app2){ref-type="sec"}E). While DENND2C knockdown does not induce differentiation, it is possible that it shares redundant function with other DENND2 proteins. We were unable to induce sufficient simultaneous knockdown of DENND2 proteins to induce differentiation in human ES cells.

We thus further examined the colony morphology phenotype caused by DENND2C, as it could provide clues for underlying molecular mechanisms. DENND2C-expressing colonies have a strikingly disorganized cortical F-actin staining pattern, which differs from the organized cortical F-actin pattern observed in WT human ES cells ([Figure 4](#fig4){ref-type="fig"}A). In addition, these cells are smaller in cell and nuclear sizes, which is more dramatic toward the interior of colonies ([Figure 4](#fig4){ref-type="fig"}A). Despite these morphological changes, these cells remain actively proliferative with no changes in either DNA content or cell-cycle profile compared with WT human ES cells ([Figure S1](#app2){ref-type="sec"}F).

The striking cytoskeletal and morphological changes in clone 2 and DENND2C-expressing cells suggested that a cytoskeletal regulator could be the potential effector of DENND2C. Thus, we tested components of several pathways regulating the cytoskeleton, cell size, and cell adhesion by stably transfecting *PB* constructs containing WT, dominant-negative, and constitutively active forms of these genes into WT human ES cells. These candidate genes were examined for morphologies similar to DENND2C expressing cells as well as the ability to block RA-induced differentiation when transfected into the PB\[NANOG\] cell line. We discovered that reduction of RHOA and RAC1 activities by the expression of dominant-negative alleles, knockdown, or direct chemical inhibition could recapitulate the DENND2C-expressing phenotypes. Downregulation of either RHOA or RAC1 causes the cells to pile into dense, multilayer colonies ([Figures 4](#fig4){ref-type="fig"}B and [S2](#app2){ref-type="sec"}A--S2F). However, only downregulation of RAC1 results in cells aggregating into balls ([Figures 4](#fig4){ref-type="fig"}B and [S2](#app2){ref-type="sec"}A). Expression of dominant-negative RAC1 (T17N, RAC1 DN) results in the small cell and nuclei phenotypes observed in DENND2C-expressing cells ([Figure 4](#fig4){ref-type="fig"}C). On the other hand, expression of dominant-negative RHOA (T19N, RHOA DN) results in altered F-actin morphology phenotypes ([Figure 4](#fig4){ref-type="fig"}C). Expression of dominant-negative RHOB or RHOC (T19N) does not elicit these morphological changes, instead triggering differentiation (data not shown), indicating that the morphological changes are specific to downregulation of RHOA activity. Finally, similar to clone 2 and DENND2C-expressing clones, cells with reduction of either RHOA or RAC1 activity maintain the expression of stemness markers ([Figure S2](#app2){ref-type="sec"}G).

Although we were unable to test the effects of RAC1 disruption in blocking RA due to its suppression of proliferation, disruption of RHOA exhibits genetic cooperation with NANOG expression in a manner similar to DENND2C to block RA-induced differentiation ([Figures 4](#fig4){ref-type="fig"}D and [S2](#app2){ref-type="sec"}D). This genetic cooperation enhances NANOG-induced repression of the endoderm differentiation trigger GATA6 ([Figure 4](#fig4){ref-type="fig"}E; [@bib7; @bib6]).

As it has been shown that chemical inhibition of the RHOA effector ROCK with the drug Y-27632 (ROCK inhibitor) results in resistance to RA, we wondered whether ROCK inhibitor treatment of NANOG expressing cells could block RA-induced differentiation ([@bib20]). However, unlike Rho inhibitor treatment, ROCK inhibitor treatment does not cooperate with NANOG to block RA-induced differentiation ([Figures 4](#fig4){ref-type="fig"}D and [S2](#app2){ref-type="sec"}D). Given that NANOG overexpression also results in the overexpression of its target OCT4, we further wondered whether OCT4 overexpression could cooperate with RHOA disruption to block RA-induced differentiation. However, this was not the case ([Figure S2](#app2){ref-type="sec"}H). These results indicate that our approach of NANOG sensitized *PB* mutagenesis is useful in identifying relevant genetic interactions with NANOG capable of blocking RA-induced differentiation.

Inactivation of RHOA and RAC1 recapitulates DENND2C-expressing phenotypes and suggests that DENND2C could be a negative regulator of RHOA and RAC1. We next examined the possibility that DENND2C physically interacts with RHOA and RAC1; however, we did not detect such interactions by co-immunoprecipitation (data not shown). We thus directly examined the activities of RHOA and RAC1 in human ES cells expressing either full-length or truncated DENND2C by immunoprecipitation of the active forms of these GTPases. Indeed, in both cases, overexpression of DENND2C results in decreased levels of active RHOA and RAC1 ([Figure 4](#fig4){ref-type="fig"}F).

DENND2C Affects Nuclear RHOA Function {#sec2.4}
-------------------------------------

Given that DENND2C negatively regulates RHOA activity, we examined whether DENND2C expression affected RHOA localization. Interestingly, while WT cells displayed RHOA staining throughout the cell, in DENND2C expressing cells, RHOA was relocalized away from the interior of the nucleus ([Figure 5](#fig5){ref-type="fig"}A). Although RHOA plays an essential role in the regulation of cytoskeleton dynamics, many of the known functions of RHOA relate to its functions in the cytoplasm (reviewed in [@bib5]). RHOA has been recently documented to reside in the nucleus ([@bib15]). In fact, actin and many actin nucleators have also been found in the nucleus, implicating functional significance for the nuclear cytoskeleton (reviewed in [@bib13; @bib39; @bib17]). While it has been shown that nuclear RHOA is activated in response to DNA damage, its function within the nucleus remains unknown ([@bib15]).

We therefore examined whether DENND2C affected the localization and activity of nuclear RHOA. By immunostaining human ES cell nuclei isolated by density gradient centrifugation, it was evident that WT and NANOG overexpressing cells contained RHOA throughout the nucleus ([Figure 5](#fig5){ref-type="fig"}B). In contrast, RHOA in DENND2C overexpressing nuclei is relocalized to the nuclear periphery ([Figure 5](#fig5){ref-type="fig"}B). We next examined the activity of RHOA in nuclear and cytoplasmic fractions of WT and DENND2C expressing human ES cells ([@bib16]). In addition to reduced cytoplasmic RHOA activation, DENND2C expressing cells have significant reduction of nuclear RHOA activation ([Figure 5](#fig5){ref-type="fig"}C). We observed similar reduction of active nuclear RHOA in the RHOA DN-expressing positive control ([Figure 5](#fig5){ref-type="fig"}C).

As a negative control, we expressed RAB35 in human ES cells, which has been implicated in the cytoplasmic transport and regulation of Rho GTPases ([@bib10; @bib33]). Indeed, expression of RAB35 inhibits cytoplasmic RHOA activity, but not nuclear RHOA activity, nor does RAB35 expression result in cooperation with NANOG in blocking RA-induced differentiation ([Figures 5](#fig5){ref-type="fig"}C and [S3](#app2){ref-type="sec"}A--S3E). Furthermore, the expression of RHOA DN tagged with a nuclear exclusion signal does not cooperate with NANOG to block differentiation ([Figure S3](#app2){ref-type="sec"}F). Together, our data suggest that DENND2C downregulates both nuclear and cytoplasmic RHOA activity, which cooperates with NANOG to block RA-induced differentiation. Indeed, nuclear RHOA is hyperactivated during RA-induced differentiation of WT human ES cells, supporting this hypothesis ([Figure S3](#app2){ref-type="sec"}G).

Given that DENND2C negatively regulates nuclear RHOA, we wondered what function RHOA had within the nucleus. Other cytoskeletal effectors are known to associate with DNA either globally or with certain promoters when activated, and furthermore, nuclear RHOA is activated in response to DNA damage ([@bib26; @bib4; @bib15]). We therefore hypothesized that nuclear RHOA may associate with DNA. Using chromatin immunoprecipitation (ChIP) with an anti-RHOA monoclonal antibody that works well for immunoprecipitation ([Figure S3](#app2){ref-type="sec"}H), we were able to pull down large amounts of DNA in undifferentiated WT and NANOG expressing human ES cells ([Figure 5](#fig5){ref-type="fig"}D). In contrast, the amount of DNA associated with RHOA in DENND2C overexpressing human ES cells is dramatically reduced ([Figure 5](#fig5){ref-type="fig"}D). The RHOA-precipitated DNA includes the *OCT4* and *GATA6* promoters, DNA from a gene desert located on chromosome 13, as well as centromeric α satellite DNA, indicating that RHOA does not exclusively associate with transcription units ([Figure 5](#fig5){ref-type="fig"}D). RHOA association with DNA was also confirmed in other human ES cell lines (H9 and parental H1; [Figure S3](#app2){ref-type="sec"}I). Overall, these data show that nuclear RHOA associates with chromatin in ES cells and that this ability is affected upon downregulation of nuclear RHOA activity by DENND2C.

Discussion {#sec3}
==========

To date, only one genome-wide genetic screen has been performed in human ES cells ([@bib11]). The high cost associated with an siRNA library can deter investigators from utilizing this approach to decipher human stem cell biology. In this study, we show that the *piggyBac* transposon can be used to conduct genetic screens in human ES cells. The ability to rapidly and cost-effectively generate a large collection of cells in which each cell has different genes mutated by simple transfection enables one to perform phenotypic-based genetic screens in human cells in a manner similar to yeast genetics. Combined with high-throughput sequencing, the genes disrupted by the *piggyBac* transposon can be easily identified, allowing one to study the molecular mechanisms underlying any biological process.

The unique ability of the *piggyBac* transposon to carry large inserts offers the opportunity to conduct sophisticated insertional mutagenesis screens ([@bib14; @bib22]). Here we were able to combine mutagenesis and simultaneous overexpression of a gene into a single transposon vector, performing a genetic screen in a sensitized background. Different from proteomic approaches, this sensitized screening strategy has the power to detect genes that cooperate in a biological process, e.g., blocking differentiation, regardless whether gene products physically interact with each other. With this strategy, we are able to probe the genome for genes capable of cooperating with NANOG, and by characterizing one of the clones, we were able to identify a poorly characterized gene, *DENND2C*, which is capable of cooperation with *NANOG* overexpression to block RA-induced differentiation. Although our *piggyBac* screen utilizes gain-of-function mutagenesis, such mutations can easily lead to the identification of loss-of-function alterations in genes in the same pathway or process, as every pathway has both positive and negative regulatory components. Indeed, we discovered that *DENND2C* is a negative regulator of RHOA. Concordantly, RHOA inactivation also cooperates with NANOG in blocking RA-induced differentiation. Although DENND2C was artificially overexpressed, we were able to phenocopy its effects with several different methods of RHOA inactivation, demonstrating that gain-of-function screens can be used to elucidate real biological mechanisms. Notably, both RHOA and DENND2C are expressed in human ES cells as well as differentiated cells and would have been missed as potential regulators of self-renewal and differentiation by more traditional approaches that focused on probing genes expressed uniquely in ES cells. Much of our understanding of RHOA comes from studies for its role in the cytoplasm as a key regulator of cytoskeleton dynamics (reviewed in [@bib5]). Recently, RHOA has been found to be located within the nucleus, and its nuclear activity is stimulated by DNA damage ([@bib15]). We found that DENND2C negatively regulates the activity of nuclear RHOA in human ES cells. Furthermore, we discovered that nuclear RHOA is associated with DNA in both coding and non-coding regions and that this association is negatively regulated by DENND2C.

In summary, forward genetic analysis by *piggyBac* gain of function mutagenesis has multiple advantages complimenting genomic and biochemical methods and empowers individual investigators to functionally interrogate the human ES cell genome to elucidate mechanisms underlying biology, disease, and therapeutic strategy.

Experimental Procedures {#sec4}
=======================

Cell Culture {#sec4.1}
------------

The H1 *OCT4*-EGFP human ES cell line was created in the James Thomson laboratory and obtained from the WiCell Research Institute under the appropriate material transfer agreement (MTA). Cells were maintained on Matrigel (BD Biosciences catalog number 354277) in a 37°C incubator at 5% CO~2~. Cells were passaged with manual dissociation with a 5-ml pipette after collagenase IV treatment (GIBCO catalog number 17104019) and maintained as originally described ([@bib34]). Additional information is in [Supplemental Experimental Procedures](#app2){ref-type="sec"}.

Transfections and Drug Selection {#sec4.2}
--------------------------------

For the screen, 9.6 × 10^7^ human ES cells were pretreated with ROCK inhibitor as described (EMD/Calbiochem catalog number 688000; [@bib38]) for 3 hr, dissociated with Accutase (Millipore catalog number SCR005), and split in single-cell suspension onto Matrigel coated six-well plates. Each well was treated with a cocktail consisting of 3-μg *piggyBac*, 1-μg PB transposase helper plasmid, 6-μl Fugene HD (Roche catalog number 04883560001), and 90-μl OptiMEM (Invitrogen catalog number 11058-021) for 48 hr. Cells containing stable *piggyBac* integration were selected with 1-μg/ml puromycin (Sigma catalog number P8833) starting 48 hr after transfection for a period of 2 weeks.

For transfections of all other *piggyBac* constructs, adherent human ES cells 2 days after passaging were treated with the same transfection cocktail and drug selection protocol.

RA Treatment {#sec4.3}
------------

Human ES cells at approximately 30% confluency in six-well plates were treated with a combination of 1-μM *all-trans* RA (Sigma catalog number R2625) and 0.2-mg/ml G418 (Sigma catalog number A1720) for 8 days. Cells were then split into 10-cm plates at a ratio of two wells to one 10-cm plate. Cells were kept on G418 for another 8 days. For the screen, surviving undifferentiated colonies were individually isolated from the 10-cm plates, expanded, and retested for RA resistance. Of an initial 50 colonies isolated, only six unique clones survived this retest. For assaying resistance to differentiation, 10-cm plates were stained for the stemness marker alkaline phosphatase (Millipore catalog number SCR004).

Mapping of Insertions {#sec4.4}
---------------------

Mapping was performed with a combination of linker-mediated PCR as described in [@bib21], splinkerette PCR as described in [@bib31] and [@bib18], and vectorette PCR as described by Carl Friddle (available at <http://www.princeton.edu/genomics/botstein/protocols/vectorette.html>). PCR products created with Taq polymerase (Denville catalog number CB4050) were TOPO-TA cloned (Invitrogen catalog number 450641), and competent cells were transformed with the resulting plasmid DNA. Individual bacterial colonies carrying an insert were picked, expanded, and DNA isolated and sequenced through the Yale Keck Sequencing Facility. True insertions were separated from PCR artifacts by the identification of PBL next to the TTAA transposition site within the sequence. Sequences identified by PCR were used to identify the location and orientation of the transposon within the genome through human BLAT search (<http://genome.ucsc.edu/>). Additional information is in [Supplemental Experimental Procedures](#app2){ref-type="sec"}.

Reverse Transcription and PCR {#sec4.5}
-----------------------------

Equal amounts of total RNA was reverse transcribed using Superscript III and oligo(dT)20 (Invitrogen catalog number 18080-051). On column DNase treatment was performed as described in the instruction manual. Semiquantitative PCR was carried out in accordance with the protocol used by [@bib12]. Quantitative real-time PCR was carried out on the cDNA using SYBR Green Supermix (Bio-Rad catalog number 172-5100). Samples were normalized to GAPDH amplification. Primer sequences available in [Supplemental Experimental Procedures](#app2){ref-type="sec"}.

Active GTPase Immunoprecipitation {#sec4.6}
---------------------------------

Immunoprecipitation of total active RHOA from 350-μg whole-cell lysate was performed with the NewEast Biosciences RhoA Activation Assay (catalog number 80601). Immunoprecipitation of active RHOA from 350-μg fractionated nuclear and cytoplasmic lysates isolated as described in [@bib16] was performed with the Cell Biolabs RhoA Activation Assay (catalog number STA-403-A). Immunoprecipitation of active RAC1 from 500-μg whole-cell lysate was performed with the Cell Biolabs Rac1 Activation Assay (catalog number STA-401-1).

Nuclear Isolation {#sec4.7}
-----------------

The protocol is as described in [@bib16].

Overexpression and Mutant Constructs {#sec4.8}
------------------------------------

All genes overexpressed in human ES cells were amplified from either human ES cell or 293T cDNA created with the Superscript III kit (Invitrogen catalog number 18080-051) with the exceptions of NANOG, which was amplified from Addgene plasmid 16578, a gift from Dr. James Thomson, and RHOA, which was amplified off Addgene plasmid 23224, a gift from Dr. Channing Der. All cDNA was amplified with MluI restriction sites and cloned into a *piggyBac* construct designed to stably overexpress the cloned gene with a β actin promoter with the sole exception of NANOG, which was overexpressed with the ubiquitin C promoter in all *PB* constructs used in this study. Dominant-negative and constitutively active constructs were created by introducing the mutations on primers and subsequent subcloning of PCR products. For assessment of cooperation with NANOG, all constructs were transfected into the same parental NANOG overexpressing cell line. Primer sequences are available in [Supplemental Experimental Procedures](#app2){ref-type="sec"}.

ChIP {#sec4.9}
----

ChIP was performed using reagents from the Pierce Agarose ChIP kit (Pierce catalog number 26156), MagnaChIP Protein AG Beads (Millipore catalog number 16-663), and 6 × 10^6^ cells (approximately two to three 10-cm plates of human ES cells) per immunoprecipitation. For each chip, we used either 2-μg NANOG antibody or rabbit IgG control (Cell Signaling catalog numbers 5232S and 2729S) or 5-μg RHOA antibody (Abcam catalog number ab54835) or mouse IgG control (Cell Signaling catalog number 5415S). Fresh chromatin and fresh antibody were incubated with 20-μl magnetic beads overnight at 4°C. Eluted chromatin was treated with RNase for 30 min prior to decrosslinking and column purification. Real-time PCR was performed in triplicate on precipitated DNA with *OCT4* promoter primers (Cell Signaling catalog number 4641S), *GATA6* promoter primers, gene desert primers ([Supplemental Experimental Procedures](#app2){ref-type="sec"}), and α satellite repeat primers (Cell Signaling catalog number 4486S). For fold enrichment calculations, the average percentage of input DNA pulled down with NANOG, or RHOA antibody was divided by the average percentage of input DNA pulled down with the relevant IgG isotype control.

Supplemental Information {#app2}
========================

Document S1. Supplemental Experimental Procedures, Figures S1--S3, and Table S1Document S2. Article plus Supplemental Information
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![*PB* Mutagenesis in *OCT4* Reporter Human ES Cells\
(A) Splicing consequences of PB\[[I]{.ul}nsertional Mutagenesis,NANOG\] (PB\[IM,N\]) insertion either in front of or within the intron of a gene. PB\[IM,N\] insertion into any reading frame is capable of inducing both overexpression of the downstream transcript with the β actin promoter and triple reading frame start cassette (not shown) as well as simultaneous expression of Katushka fluorescent marker by the splicing of Katushka/IRES into the native transcript with the splice donor (SD). This construct is also able to create N-terminally truncated transcripts with the splice acceptor, triple reading frame stop cassette, and poly A tail (SA-stop-pA). PB\[IM,N\] can also constitutively overexpress *NANOG* transcript from the independent *NANOG* overexpression cassette.\
(B) (Top) FACS analysis of Katushka expression from PB\[IM,N\] in human ES cells 48 hr after transfection in single-cell suspension using the RFP channel. Mean of triplicate independent experiments is shown. Error bars represent SD. (Bottom) *PB* copy number within ten individual PB\[IM,N\] transfected human ES cell clones as assessed by real time PCR. There is a mean of five PB\[IM,N\] insertions per clone.\
(C) Protocol of screen performed in H1 *OCT4*-EGFP cells for resistance to RA-induced differentiation using PB\[IM,N\]. Cells in six-well plates were transfected with PB\[IM\]N, puromycin selected, and subsequently treated with RA and G418. Cells were then split from the six-well plates into 10-cm plates at a 2:1 ratio and maintained on G418 alone.\
(D) Brightfield and fluorescent images of the six unique clones recovered from the screen. All clones are positive for EGFP and Katushka fluorescent reporters for *OCT4* expression and PB\[IM,N\] insertion within an actively expressed gene.](gr1){#fig1}

![NANOG Expression from *PB* Constructs Induces Resistance to RA-Induced Differentiation\
(A) OCT4 immunostaining in WT and NANOG expressing human ES cells. NANOG expressing cells resist spontaneous differentiation and maintain OCT4 signal in colony centers at larger diameters than WT cells. Scale bar represents 100 μm.\
(B) (Top) Morphology of RA differentiated cells. The red square highlights a cluster of morphologically undifferentiated NANOG expressing cells after RA treatment, magnified in inset. Scale bar represents 200 μm. (Bottom) RT-PCR analysis of RA-differentiated cells.\
(C) Immunostaining of RA-differentiated cells co-stained for NANOG and GATA6. RA induces differentiation of human ES cells as assessed by GATA6 endoderm marker. Scale bar represents 150 μm.\
(D) Real-time PCR (top) and western blot (bottom) analysis of stemness marker expression in RA-treated cells. The addition of a NANOG overexpression cassette to PB\[IM\] induces protein overexpression of both NANOG and the NANOG target OCT4 and induces weak persistence of NANOG and OCT4 after RA treatment. Graph shows mean of triplicate independent experiments. Error bars represent SD. ^∗∗^p \< 0.001 in Student's t test.\
(E) Alkaline phosphatase staining of combined RA/G418-treated cells after 16 days. Experiments are performed in duplicate. A representative plate is shown.](gr2){#fig2}

![*PB* Mutagenesis of *DENND2C* Causes Morphological Changes and Resistance to RA\
(A) (Top) Screenshot from the UCSC Genome Browser detailing the position and orientation of the PB\[IM,N\] insertion in *DENND2C* mapped in clone 2 (red arrow). (Bottom right) PB\[IM,N\] insertion results in overexpression of the C-terminal half of DENND2C, made up primarily of its DENN domain. (Bottom left) The C terminus of DENND2C is significantly upregulated in clone 2 by real-time PCR. Graph shows mean of triplicate technical replicates, and error bars represent SD. ^∗∗^p \< 0.001 in Student's t test.\
(B) Brightfield and *OCT4*-EGFP reporter images of clone 2 and DENND2C expressing human ES cells. Clone 2 aggregates into either balls of cells or flat, extremely dense colonies that resist spontaneous differentiation. Cells stably transfected with full-length (FL) or truncated (TR) DENND2C also display this behavior. Scale bar represents 50 μm.\
(C) RT-PCR showing maintenance of stemness in DENND2C expressing human ES cells, which do not display markers of differentiation.\
(D) Western blot demonstrating that DENND2C overexpressing cells produce NANOG and OCT4 proteins at levels comparable to the parental WT and NANOG overexpressing cell lines. Overexpressed DENND2C-FL runs as a doublet, while only DENND2C-TR lysate exhibits a band running at the predicted 50 kDa of truncated DENND2C.\
(E) Alkaline phosphatase-stained plates after RA/G418 treatment. Experiments were performed in triplicate. A representative plate for each set of experiments is shown.\
See [Figure S1](#app2){ref-type="sec"} for additional information.](gr3){#fig3}

![DENND2C Phenotype Is Induced by Loss of Active RHOA and RAC1\
(A) DAPI and F-actin immunostaining of WT and DENND2C expressing human ES cells. Scale bar represents 30 μm.\
(B) Brightfield and *OCT4*-EGFP reporter images of cells stably expressing dominant-negative RHOA T19N (RHOA DN) and dominant-negative RAC1 T17N (RAC1 DN). Scale bar represents 50 μm.\
(C) DAPI and F-actin immunostaining of WT and RHOA DN and RAC1 DN mutant human ES cells. Scale bar represents 30 μm.\
(D) Plates stained for alkaline phosphatase after RA/G418 treatment. Experiments were performed in triplicate. A representative plate for each set of experiments is shown.\
(E) The induction of lineage markers with RA assessed by real-time PCR. RA treatment induces differentiation as reflected by the induction of the endoderm marker GATA6. NANOG expression from *PB* induces some repression of GATA6 and no upregulation of endogenous NANOG. NANOG/DENND2C and NANOG/RHOA DN cells display enhanced repression of GATA6 and upregulation of endogenous NANOG at the RNA level. Graph shows mean of triplicate independent experiments. Error bars represent SD. ^∗∗^p \< 0.001, ^∗^p \< 0.05 in Student's t test.\
(F) Immunoprecipitation of active RHOA and RAC1 in DENND2C expressing cells. DENND2C expressing cells have decreased active RHOA and RAC1 relative to WT cells.\
See [Figure S2](#app2){ref-type="sec"} for additional information.](gr4){#fig4}

![DENND2C Negatively Regulates Nuclear RHOA Activities\
(A) DAPI and RHOA immunostaining of WT and DENND2C expressing ES cell colonies. Scale bar represents 10 μm.\
(B) DAPI and RHOA immunostaining of isolated WT and DENND2C expressing nuclei. Scale bar represents 3 μm.\
(C) Immunoprecipitation of active RHOA from nuclear and cytoplasmic fractions of WT and mutant cells. DENND2C and RHOA DN cells have reduced active RHOA in both nuclear and cytoplasmic fractions. Cytoplasmic RHOA inhibitor (RAB35) is included as a negative control.\
(D) ChIPs performed in human ES cells with a RHOA monoclonal antibody and NANOG-positive control antibody. Presented is the average fold enrichment over IgG control of the *OCT4* promoter, *GATA6* promoter, chromosome 13 gene desert, and α satellite DNA. Error bars represent the mean percent fold enrichment over IgG control ± the SEM for triplicate technical replicates.\
See [Figure S3](#app2){ref-type="sec"} for additional information.](gr5){#fig5}
